Distressed Investing Forum

On July 31 we took a global walk through quick-paced briefings that examined issues from opioids in the U.S. to Venezuela to the Chinese bubble to the just finalized EU restructuring law...

Off-Label Medical and Scientific Information: Reconciling the FDA's Regulatory Mandate with the First Amendment Commercial Free Speech Doctrine

John Osborn spoke on regulatory and legal developments concerning off-label medical information to health policy scholars at the Schaeffer Center for Health Policy and Economics at the...

Biomedical Innovation and Access to Health Care

John Osborn discussed the problem of reconciling biomedical innovation and access to health care with public health, business, and medical students and faculty at the Dartmouth Institute...

Managing Communications Between Manufacturers and Payers: Promotional Messages, Financial Contracting Negotiations, and Commercial Free Speech

John Osborn was on a panel at the Global Health Care Pharmaceutical Summit on Business & Compliance Issues in Managed Markets in Washington, D.C. which addressed the subject of...

The Freeing of Off-Label Medical Product Use Information

John Osborn participated in a media briefing at the Washington Legal Foundation on "The Freeing of Off-Label Medical Product Use Information" that was held on 2 May 2016.

Watch video of the ...

Loading data